On the website Diagnosis of erectile dysfunction full Specifications how to take these tablets. Be sure to check before use.

Je l'ai acheté le médicament cialis prix deux ou trois fois, l'effet est des pilules superbes, je ne ne nous a pas déçus même si je suis au dernier étage sur la pilule. Männer werden empfohlen, für mindestens 30 Minuten für den angeblichen Geschlechtsverkehr durchschnittliche Rendite von cialis 20mg zu verwenden.

Microsoft powerpoint - select mar 2006




HEALTH CARE BENEFITS IN CANADA
March 2006
We Take a Closer Look Wendy Murkar
Vice-President, Claims Administration
Green Shield Canada
ƒ State of health care in Canadaƒ Issues affecting benefit utilization ƒ Impact on benefit plan design



STATE OF HEALTH CARE
IN CANADA
Benchmarking of
Canada's Health Care System
ƒ Canada and 23 other countries benchmarked on 24 health status indicators Conference Board of Canada ƒ Canada's results: • Middle of pack -13th overall out of the 24 countries• 3rd highest in total health spending • 6th highest public spender• Spending as a % of Gross Domestic Product - 7.4%, one of the highest in world



Health of Canadians
ƒ Benchmarking results: • Good on health status indicators i.e. life expectancy, low birth weight etc. • 20th out of 23 on health outcomes i.e. lung cancer rates, myocardial infarcts, stroke rates, breast cancer, suicide etc.
• 6th in obesity• 2nd highest sulphur dioxide emission * CIHI (Canadian Institute for Health Information) ƒ In Feb 2006 Conference Board of Canada issued a report benchmarking the health of Canadians by province – health status, healthcare outcomes, utilization and • No province does well in all areas• British Columbia and Alberta have top performance but B.C. lowest satisfaction level • Higher spending not associated with better health • Ontario – second lowest female life expectancy, second highest low birth weights, very low satisfaction levels but shortest wait times


Issues – Health Care
ƒ Canadians have high expectations versus other countries and do not use health care resources effectively – i.e. high incidence of emergency room use.
ƒ 2004 estimated health spending – $130.1 billion* • Public spending more than $91.1 billion ƒ Canada performing okay – male life expectancy, mortality rates on strokes, incidence of AIDS ƒ Canada performing poorly and needs attention to: • obesity, prostate cancer, infant mortality, female lung cancer, breast cancer and colorectal cancer *Conference board of Canada Costs of Health Care
Total Health Care Spending
Billions
Costs - Health Benefits
Benefit plan costs (Conference Board):
1990 – 3.7% of payroll
2003 – 6% of payroll
2007 – expected to reach 8% of payroll
Cost Drivers
ƒ Aging populationƒ Diminishing demographicsƒ Increasing consumer and provider expectations ƒ Cost of chronic disease ƒ Health human resources: • Access• Patient safety• Environmental issues ƒ Pharmaceuticalsƒ Home care ƒ Expectations for quick access to sophisticated and high quality services will continue to grow ƒ Failure to match the expectations of the providers and consumers will lead to the erosion of universality for services not deemed medically necessary (hip /knee replacements, etc) ƒ First wave of boomers – age 65 in 2012, but they will attempt to hold onto their youth – watch grandma windsurf - new drugs to do so.
ƒ Accountability and access on every Government agendaƒ Chaoulli ruling opened door to two tier Heath Care Health Council of Canada
2005 Health Care Summit's Goals for New Health
Funding: their solution and how we fix the problem
ƒ Reduce waiting timesƒ Add health professionalsƒ Home care – expand services ƒ Health innovation – HER (electronic health records), prescribing, science, research ƒ Primary care reformƒ National RX (catastrophic) strategyƒ Prevention promotion and public health National Pharmaceutical Strategy
By June 2006 a Report on Progress Including Options for:
ƒ Catastrophic coverage (national)
ƒ National Drug Formulary
ƒ Strengthening evaluation of drug safety and effectiveness
ƒ Pursuing purchasing strategies
ƒ Influencing prescribing patterns – drugs only used when needed
ƒ Expanding access to non-patented drugs, pricing information
ƒ Better analysis of cost drivers, best practices etc.
ƒ Increasing e-prescribing and deployment of EHR (electronic health records)
Ontario Drug Secretariat
ƒ Appointed mid 2005 by Minister Smithermanƒ Ontario Drug Benefit Plan unsustainable and not achieving results needed to increase health of Ontarians ƒ Report was tabled January 2006 – consulted with all external stakeholders including benefit plan sponsors ƒ Report not yet released. changes will be forthcoming and implemented over next year + ƒ Will form basis of Ontario's response to National Catastrophic Drug plan National Pharmaceutical Strategy
Issues
ƒ Income based eligibility:
• With up front out of pocket expense required • 5% to 10% of taxable income estimated as out of pocket • No Canadian to be financially disadvantaged because of drug National Pharmaceutical Strategy
Issues
ƒ Formularies will be limited and drugs will be reviewed before added
(time delays) and will consider cost/value equation. some drugs now covered by province may not be . i.e. basic meds like PPI's may be ƒ Out of Pocket to qualify will increase (Ontario - now one of lowest)ƒ May introduce other things like Maximum Allowable Costs in therapeutic classes . (drug plans pick up slack if not dealt with in plan language) ƒ Few employer plans currently have annual or life time maximums nor do they restrict medications i.e. limited or managed formularies ƒ Without changes the concern is most plans will automatically pick up shortfall – plan wording will be significant go forward issue Changes to Drug Costs as a Result
ƒ Bulk purchasing by provinces ƒ National catastrophic drugs could force up prices to private sector ƒ Drug pricing strategies: • Manufacturers listed prices not what drug sells for • Possibly change/influence Primary Health Care Reform
ƒ Fundamental to improving our health care system and making it sustainable and accessible ƒ Built on four pillars • Teams• Information ( E.H.R)• Access• Health Living Primary Health Care Reform
ƒ Interdisciplinary teams working cooperatively – doctors, nurses , pharmacists, physiotherapists, nutritionists etc. ƒ Shared information across all health professionals (E.H.R.- electronic health record and diagnosing tools ) ƒ Access beyond office hours -goal 50% of Canadians have access to 24/7 by 2011 ƒ Health living, chronic disease prevention ,management ISSUES AFFECTING BENEFIT
UTILIZATION AND COSTS
ƒ 16 million Canadians live with a chronic disease: cardiovascular, cancer, mental illness, diabetes, chronic obstructive lung ƒ Chronic disease accounts for 87% of disability ƒ Chronic disease accounts for 67% of all direct health care costs and 60% of The Most Important Common Risk Factors*:
ƒ Smoking including exposure to second-hand smoke
ƒ Obesity – 48% of Canadians are overweight;
ƒ Physical inactivity – 56% of Canadians are inactive; only 18% of teenagers active enough to meet international guidelines * Conference Board Mental Health &
Work Life Conflict
ƒ $16 billion or 15% of payroll is the economic impact of work related health and mental health issues Job stress
ƒ Work life conflict adds $6 billion 60% of Canadians indicate they can't balance work and family life Addiction
Back pain
On the job injuries
ƒ By 2020, depressive disorders will become one of the leading cause of disease burden in Canada; represents anywhere from 4% to 12% of payroll costs in Canada.
ƒ Depression & stress disorders at work account for more than 30% of disability claims ƒ Mental health claims are the fastest growing category of disability costs in Canada (overtaking cardiovascular disease) Source: Canadian Mental Health Association
ƒ 3 million Canadians depressed ( 10% of population)ƒ 1.4 million working Canadians depressed ( 10% of labour ƒ Over 33% of teenagers likely to experience depressionƒ 8% of Total Drug Expenditure in 2004 Source: Global Business And Economic Roundtable on Addiction And Mental
Health

Home Care
ƒ Home Care is considered an Extended Health Care Service under the Canada Health Act and is deemed a non-insured service ƒ Currently no strategy in Canada to address home care ƒ Throughout the 1990's the cost of home care increased at an annual rate 4X greater than other health care spending (not pharmaceuticals) ƒ Significant cost off loaded to drug plans and growing Escalating Drug Costs
ƒ CIHI reports drug spending at $22 billion (5x > than in 1995) ƒ Public sector finances only 37.6% of cost of prescription drugs Escalating Drug Costs
ƒ 1980's; $1.00/day was considered expensive (e.g. Tagamet, Zantac) ƒ Today's barrier has been estimated ƒ Biologics (DNA technology) – next wave of pharmaceuticals – over 800 in development - 350 in late stages of development Escalating Drug Costs
Average Prescription Price*
* HKS & Company, Warren, NJ, Academy of Managed Care Pharmacists, 2003 % of all pipeline
0% 3% 5% 8% 10% 13% 15% 18% 20% 23% 25% Antineoplastic & Immunosup.
Central Nervous System Cardio & Lipid.
drugs that treat
specialty
Anti-infective Agents Hormones & Synthetic Subst.
Skin & Mucous Memb. Prep.
Autonomic Agents, Agent for Specific
Disease, Enzymes, Diagnostic Agents,
Electrolytic & Water Balance, Sexual

for cervical cancer
Disorder, Musculoskeletal, etc.
New Drugs
Drug Name
Rheumatoid Arthritis $10,000 - $34,000 * Replax®
Colorectal Cancer ƒ Growing scope of pharmacotherapy: • New treatments for diseases• Maintenance medication • Preventative medication• Multiple medications – same condition ƒ More consumer driven demandƒ Direct marketing to physicians by drug companies ƒ 5% of claimants have highest drug costs - more than 40% of all costs ƒ Average utilization of high costs claimants - heavily weighted to 55-64 year old age group ƒ Selected therapy users average costs - $11,500 + • Cancer, Rheumatoid Arthritis, Multiple sclerosis, HIV, ƒ Multiple chronic diseases - average annual use $17,251 "Study of how an individuals genetics affects the
body's response to drugs"
ƒ 1/3 of drugs in testing are genetic/biologic . ƒ Estimate is that about 50 of the top 100 drugs ( anti depressants, pain meds etc. ) are affected by "one metabolizing enzyme" – 5-8% of Caucasians, 70% of Asians have some defect in this gene strand.
ƒ Statin study Iceland – 10,000 users – 2,000 no effect at all 20% ƒ Development of predictive genetic tests – prevention, planning ƒ Will ensure the right drug for the right patient - better, safer. more powerful drugs- which could decrease overall costs ƒ Extremely high cost entitiesƒ More drugs coming to market for previously untreated/under treated diseases ƒ Patents are being awarded on genetic markers/testing (no cost controls) ƒ 2003 in U.S. > 1 million genetic tests performed ƒ Market growing by 30% per year ƒ In use at University of Montreal and Genome Quebec: • Childhood leukemia • Antidepressants • Pain medication• Herceptin (breast cancer) ƒ Test costs – who pays? (U.S. – some drug plans pay)ƒ Complexity in deciphering gene variations and interpretation of testing on drug response – who can do it ƒ How do you ensure information is used by physician and not just another alternative.
ƒ How does physician/pharmacist apply to prescription/dosingƒ Disincentives for drug companies - limits their markets ƒ Limited drug alternatives – if does not work • Education – public and health care providers Electronic Health Record
Objectives:
ƒ Improve health outcomes
ƒ E-prescribing – reduce error rates,
improve patient safety ƒ Improve decision making ƒ More efficient use of resources ƒ Permit remote access – Electronic Health Record - Model
The Old World
The New World
Patient and family focus Continuum of care Episode management Disease management Supply management Demand management Lone Ranger decisions Collaborative, evidence- based Decentralized care Centralized, specialized Electronic Health Record Issues
ƒ Costs of implementation – technology, cognitive fees, transaction fees, consent etc.
ƒ Compliance with standards by all providers – adds costsƒ Privacy- knowledgeable patientsƒ Plan Adjudication increased sophistication new information, new standards, new plan types ƒ Emergence of e-prescribing will affect : • formulary design, utilization of pharmaceuticals• the current supply chain Impact on Benefit Plan Design
Impact on Benefit Plan Design
ƒ Existing publicly funded benefits will be significantly changed: • More off-loading, home care, drugs for home use - cancer therapy oral not IV • Income based –provincial coverage • Limited use drugs and drugs not on formularies - increasing ƒ Current benefit plans can not meet all expectations – high cost drugs may be available only to a few people, need to consider ƒ Shift from "paternal view" of taking care of employees to "shared ƒ Plan sponsors will have to make choices – focus on sustainable costs Impact on Benefit Plan Design
ƒ If issues with access not addressed: • 2 - tier pricing• Private clinics/Private referrals ƒ EHR will add costs to the delivery model - cognitive fees, transaction fees, password maintenance, consent maintenance etc.
ƒ National Catastrophic Drug Plan - how does plan language ensure plan members are protected? ƒ National Pharmaceutical Strategy Impact on Benefit Plan Design
Plan Members
ƒ Plan members will demand expansion of covered services i.e. value of semi private in relation to other "at ƒ High costs for new tests/diagnostics will have to be evaluated and costed –when they bring value, who ƒ MRI in private clinic for active employee only – get employee back to work ƒ All benefits and services will have to be reviewed to ensure they meet medically necessary criteria of improved health outcomes . Vision care every two years- cosmetic or a health requirement Impact on Benefit Plan Design
ƒ Benefit plan language needs to address ƒ traditional drug language probably not appropriate, consider if language covers drug ingredient costs alone, - delivery chain and primary health cognitive fees, amount covered if care model (Canada Health Act) physician dispenses etc.
- reimbursement model ƒ Consider costs transactions, private ƒ The requirement to use any government coverage as first payer.
ƒ Introduction of new costs from ƒ Give employer alternatives with cost implementation of emerging initiatives: containment – right person, right drug - picked up by existing language - significant pressure to add ƒ Overall plan maximums , so as additional costs are added exposure does not increase. Impact on Benefit Plan Design
Chronic Disease and Mental Health
ƒ Costs of diagnoses and treatments ƒ Provide education and prevention ƒ Prevention and healthy lifestyle need to ƒ Have a healthy life focus be encouraged and rewarded ƒ Put attention to employees versus dependents and spouses – i.e. physio for active only not dependents ƒ Reward good consumerism and healthy choices through plan design Impact on Benefit Plan Design
ƒ If expectations are not dealt with - ƒ Offer co-pays, deductibles, maximums, costs unsustainable increased off-loading to public plans ƒ Generic vs. Brand drugs, Maximum ƒ Flexible technology and ongoing due diligence allowed costs, EGS to ensure maximum coordination with all ƒ Off-loading from Government ƒ Move to formularies that same or similar restrictions that government wil or picking up costs - Conditional Drug Formulary- prescribing guidelines ƒ Coverage for preventive services enhanced , chronic decreased, ƒ Flex Benefits ® Impact on Benefit Plan Design
Education and Interventions
ƒ Plan members have high ƒ Communicate cost/value of current plan and benefits plan, expectations – but not everything covered all the ƒ Education to make better decisions ƒ Ensure patients understand impact of treatment options – plan design must force choices ƒ Coverage personalized to ƒ Begin philosophy of not everything covered – lag fee health condition, level of guides eliminate things cosmetic alone.
compliance (diabetic - benefit of dietician), target "at risk" ƒ Reward good lifestyle choices e.g. (nicotine patches covered) ƒ Reward good consumerism - (generic drugs – lower ƒ Health care spending account to deal with diverse needs and offer protection from delisting, new costs and services Frivolous Cost or Sound Investment?
ƒ Conference Board of Canada– Dec. 2005 • Very difficult in turbulent times ( survive today is focus)• Absenteeism and disability rates for "personal" reasons • Rising drug and dental costs, cost shifting from public sector is significant concern • Still uncertainty of results and the link to productivity and competitiveness is tenuous.
• Research has evidence of the relationship between employee satisfaction and profitability, higher employee • ROI on workplace health promotion wrong debate – focus has to be strategic and long term.
Green Shield Canada
Right Benefit, Right Person, Right Time:
ƒ Green Shield Canada Conditional
Drug Formulary ƒ Initial Days Supplyƒ Enhanced Generic substitution and Maximum Allowed Costs ƒ Claims Management – Green Shield ƒ Green Shield Canada Passport to Healthƒ Reporting and Analysis – Web ShieldStats®

Source: http://www.selectpath.ca/Employers/Resources/pres_2006_Closer_Look.pdf

Importancia del agua

Elementalwatson "la" revista ………………. Revista cuatrimestral de divulgación "En el conocimiento y la cultura no Año 4, número 11 sólo hay esfuerzo sino también placer. Llega un punto donde estudiar, o investigar, o Universidad de Buenos Aires Ciclo Básico Común (CBC) aprender, ya no es un esfuerzo y es puro

Systemic hypertension

Systemic hypertension Disease Coverage Report reference: DMKC12591 Published on: 27/06/2016 About Datamonitor Healthcare Bringing you a clearer, richer and more responsive view of the pharma & healthcare market. Complete market coverage Our independent research and analysis provides extensive coverage of major disease areas,